alexa
Reach Us +44-1235425476
New Application of Chemical Biology | OMICS International
ISSN: 2155-9619
Journal of Nuclear Medicine & Radiation Therapy

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

New Application of Chemical Biology

Liqiang Zhang*

Center of Bio Energetics, The Biodesign Institute, Arizona State University, USA

*Corresponding Author:
Liqiang Zhang
Center of Bio Energetics
The Biodesign Institute, Arizona State University
USA
E-mail:[email protected]

Received date: July 01, 2012; Accepted date: July 05, 2012; Published date: July 07, 2012

Citation: Zhang L (2012) New Application of Chemical Biology. J Nucl Med Radiat Ther S7:e001. doi:10.4172/2155-9619.S7-e001

Copyright: © 2012 Zhang L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Visit for more related articles at Journal of Nuclear Medicine & Radiation Therapy

It is hard to search when people tried to develop chemical approaches for biological research, but the term of “chemical biology” has come into wide use for not more than two decades. As a complex hybridization of chemistry, biochemistry, biology and pharmacology, chemical biology has made numerous triumphs with booming biomedical science in the last decade [1].

Except the application of NMR and mass spectra (MS) to the research of biology, another well known accomplishment of chemical biology is synthetic small-interfering RNA (siRNA) duplexes. Now it is one of the most powerful tools for biological mechanism study by lossof- function assay. Besides successes in research tools, chemical biology has made very prominent progress in the field of diagnostics. No doubt, to develop lower-cost and easier approaches with higher sensitivity and specificity is only direction of chemical biology in future. Scientists have made very significant successes recently, such as nanoparticles for targeting and visualizing tumor tissues [2], DNA synbodies which is new affinity reagent that could offer an easy-to-produce alternative to traditional antibodies [3]. Researchers are also trying to develop new sensors to diagnose HIV at low cost [4].

Chemical biology has not only been applied to the development of probes, but also has made remarkable success in drug discovery. Since the development of imatinib (Gleevec), which is the first of new drugs acting as a specific inhibitor to a certain enzyme, was cited as a major success for chemical biology [5], couple of other specific inhibitors to certain enzyme (most are kinase) or receptor have been developed and tested, such as inhibitors of phosphoinositide 3- kinase (PI3-K) and inhibitors of epidermal growth factor receptor (EGFR). Some of them have been approved by US Food and Drug Administration (FDA).

Considering the disadvantages of nuclear medicine and limits of radiation therapy, chemical biologist may bring into full play the advantage of chemical biology in specific cellular targeting to improve those disadvantages and overcome limits in the short future.

References

  1. Bucci M, Goodman C, Sheppard TL (2010) A decade of chemical biology. Nat Chem Biol 6: 847-854.
  2. Fan K, Cao C, Pan Y, Lu D, Yang D, et al. (2012) Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat Nanotechnol 7: 459-64.
  3. Liu R, Jiang B, Yu H, Chaput JC (2011) Generating DNA synbodies from previously discovered peptides. Chembiochem 12: 1813-1817.
  4. www.grandchallenges.org
  5. [No authors listed] (1998) Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • World Conference on Clinical and Medical Case Reports
    Mar 16-17-2020 Hong Kong, Hong Kong
  • 5th International Conference on Clinical & Medical Case Reports
    April 16-17, 2020 Amsterdam, Netherlands

Article Usage

  • Total views: 12268
  • [From(publication date):
    specialissue-2015 - Feb 21, 2020]
  • Breakdown by view type
  • HTML page views : 8468
  • PDF downloads : 3800
Top